Issue
The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.
Amyloid beta directed antibody for Alzheimer's disease, an evidence based meta-analysis
Corresponding Author(s) : C Li
Cellular and Molecular Biology,
Vol. 62 No. 4: Issue 4
Abstract
In several preclinical researches, antibody of Aacting directly in the central nervous system showed a great efficacy on the clearance of plaques. However, the other researches were opposite. We performed a meta-analysis to evaluate the amyloid-beta-directed antibody treatment of Alzheimer's disease. We searched Pubmed, Web of science, Embase and Cochrane library. Pooled data was calculated by standard mean difference. The heterogeneity and publication bias were evaluated by I2 and funnel plot. Totally, 5 RCTs (randomized clinical trials) with high qualities were included. There weas no difference of mean change form baseline between therapy and placebo group based on Mini-Mental State Examination (MMSE, SMD = 0.00, p = 0.97, 95% CI = -0.23 0.22) and Clinical Dementia Rating–Sum of Boxes (CDR-SB, SMD = 0.22, p = 0.39, 95% CI = -0.28 0.71), but a significant decrease according to Alzheimer's Disease Assessment Scale (ADAS-cog, SMD = 0.07, p = 0.01, 95% CI = -0.02 0.13). In conclusion, Antibody was not benefit for AD based on MMSE and CDR-SB but had a little effect according to ADAS-cog.
Keywords
Antibody
amyloid beta
Alzheimer's disease
therapy
meta analysis
systematic review.
Li, C., Ma, Q., Chen, S., Feng, J., & He, Y. (2016). Amyloid beta directed antibody for Alzheimer’s disease, an evidence based meta-analysis. Cellular and Molecular Biology, 62(4), 83–87. Retrieved from http://cellmolbiol.org/index.php/CMB/article/view/845
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX